No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 67 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Breast Cancer Survivor Thanks Early Detection For Saving Her Life April 6, 2021 New Drugs Raise Old Questions about Treating Cancer during Pregnancy May 25, 2022 EMA Recommends Granting a Marketing Authorisation for Celdoxome Pegylated Liposomal September 1, 2022 Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly... August 31, 2020 Load more HOT NEWS Study Suggests that Cancer Patients Who Eat Peanuts Frequently May Be... FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... FDA Approves Pralsetinib for Lung Cancer with RET Gene Fusions Coronavirus Vaccines and People with Cancer: A Q&A with Dr. Steven...
